BEAM
Price
$21.37
Change
-$0.55 (-2.51%)
Updated
Nov 19, 01:33 PM (EDT)
Capitalization
2.23B
104 days until earnings call
Intraday BUY SELL Signals
RGNX
Price
$11.05
Change
-$0.20 (-1.78%)
Updated
Nov 19, 01:58 PM (EDT)
Capitalization
569.26M
104 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BEAM vs RGNX

Header iconBEAM vs RGNX Comparison
Open Charts BEAM vs RGNXBanner chart's image
Beam Therapeutics
Price$21.37
Change-$0.55 (-2.51%)
Volume$2.06K
Capitalization2.23B
REGENXBIO
Price$11.05
Change-$0.20 (-1.78%)
Volume$1.37K
Capitalization569.26M
BEAM vs RGNX Comparison Chart in %
BEAM
Daily Signal:
Gain/Loss:
RGNX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BEAM vs. RGNX commentary
Nov 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and RGNX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 19, 2025
Stock price -- (BEAM: $21.94 vs. RGNX: $11.24)
Brand notoriety: BEAM and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 64% vs. RGNX: 92%
Market capitalization -- BEAM: $2.23B vs. RGNX: $569.26M
BEAM [@Biotechnology] is valued at $2.23B. RGNX’s [@Biotechnology] market capitalization is $569.26M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 1 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • BEAM’s FA Score: 1 green, 4 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, both BEAM and RGNX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 3 TA indicator(s) are bullish while RGNX’s TA Score has 3 bullish TA indicator(s).

  • BEAM’s TA Score: 3 bullish, 8 bearish.
  • RGNX’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, RGNX is a better buy in the short-term than BEAM.

Price Growth

BEAM (@Biotechnology) experienced а -2.40% price change this week, while RGNX (@Biotechnology) price change was -2.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.28%. For the same industry, the average monthly price growth was -5.78%, and the average quarterly price growth was +64.73%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 03, 2026.

RGNX is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (-2.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.23B) has a higher market cap than RGNX($569M). RGNX YTD gains are higher at: 45.472 vs. BEAM (-11.532). RGNX has higher annual earnings (EBITDA): -129.93M vs. BEAM (-414.33M). BEAM has more cash in the bank: 1.15B vs. RGNX (323M). RGNX has less debt than BEAM: RGNX (77.7M) vs BEAM (155M). RGNX has higher revenues than BEAM: RGNX (156M) vs BEAM (60.3M).
BEAMRGNXBEAM / RGNX
Capitalization2.23B569M391%
EBITDA-414.33M-129.93M319%
Gain YTD-11.53245.472-25%
P/E RatioN/AN/A-
Revenue60.3M156M39%
Total Cash1.15B323M356%
Total Debt155M77.7M199%
FUNDAMENTALS RATINGS
RGNX: Fundamental Ratings
RGNX
OUTLOOK RATING
1..100
71
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
45
P/E GROWTH RATING
1..100
17
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BEAMRGNX
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 7 days ago
76%
Declines
ODDS (%)
Bearish Trend 7 days ago
84%
Bearish Trend 3 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
66%
View a ticker or compare two or three
Interact to see
Advertisement
BEAM
Daily Signal:
Gain/Loss:
RGNX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SPMAX11.85N/A
N/A
Saratoga Mid Capitalization A
BMCCX19.92N/A
N/A
BlackRock Advantage Large Cap Gr Inv C
TRLHX24.82N/A
N/A
Nuveen Large Cap Value I
MAIHX20.71N/A
N/A
Morgan Stanley Inst Passport ovrs eq IR
VCSOX28.47-0.45
-1.56%
VALIC Company I Intl Sclly Rspnb

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
-0.36%
CRSP - BEAM
70%
Closely correlated
-3.34%
RXRX - BEAM
62%
Loosely correlated
+0.97%
PRME - BEAM
61%
Loosely correlated
-7.59%
NTLA - BEAM
61%
Loosely correlated
-0.12%
AXON - BEAM
57%
Loosely correlated
-1.74%
More

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with SYRE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
+0.94%
SYRE - RGNX
57%
Loosely correlated
-1.07%
DNLI - RGNX
56%
Loosely correlated
+0.58%
RXRX - RGNX
54%
Loosely correlated
+0.97%
BEAM - RGNX
54%
Loosely correlated
-0.36%
ARWR - RGNX
54%
Loosely correlated
+0.82%
More